Biotech Movers

Updated May 31, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

428 active tickers0 with insider buys37 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
PCVX Vaxcyte Inc.	Exited Perceptive Advisors, EcoR1 Capital +7	3	—	245d Ph3	155
DYN Dyne Therapeutics Inc.	Exited RTW Investments, EcoR1 Capital +7	1	—	—	135
CMPS COMPASS Pathways plc	Trimmed Driehaus Capital, Eventide Asset Management +5	2	—	30d Ph3	125
RNA Avidity Biosciences Inc.	Exited RA Capital Management, OrbiMed Advisors +5	4	—	92d Ph3	125
RVMD Revolution Medicines Inc.	Added Baker Bros. Advisors, Avoro Capital Advisors +3	3	—	30d Ph3	120
AKRO Akero Therapeutics Inc.	Exited Perceptive Advisors, Deerfield Management +5	4	—	—	120
PRAX Praxis Precision Medicines, Inc.	Added Driehaus Capital, Cormorant Asset Management +3	3	—	30d Ph3	120
SYRE Spyre Therapeutics, Inc.	Trimmed Commodore Capital, Driehaus Capital +4	2	—	30d Ph2	110
BPMC Blueprint Medicines Corporation	Exited Baker Bros. Advisors, Driehaus Capital +5	2	—	214d Ph2	110
CELC Celcuity Inc.	Trimmed Eventide Asset Management, Avoro Capital Advisors +4	2	—	30d Ph3	110
CYTK Cytokinetics Incorporated	Exited Driehaus Capital, Avoro Capital Advisors +5	2	—	—	105
IDYA IDEAYA Biosciences Inc.	Added Baker Bros. Advisors, Cormorant Asset Management +2	4	—	22d Ph2	105
ARWR Arrowhead Pharmaceuticals Inc.	Added Avoro Capital Advisors, Commodore Capital +4	1	—	—	100
RYTM Rhythm Pharmaceuticals Inc.	Held Rock Springs Capital, Driehaus Capital +3	5	—	153d Ph2	95
RCKT Rocket Pharmaceuticals Inc.	Exited EcoR1 Capital, Avoro Capital Advisors +3	3	—	184d Ph3	95
TVTX Travere Therapeutics Inc.	Exited OrbiMed Advisors, Driehaus Capital +3	1	—	30d Ph2	95
CGON CG Oncology, Inc.	Exited RA Capital Management, BVF Partners +2	3	—	30d Ph2	95
MDGL Madrigal Pharmaceuticals Inc.	Exited OrbiMed Advisors, Perceptive Advisors +4	2	—	214d Ph3	95
GPCR Structure Therapeutics Inc.	Exited Perceptive Advisors, Driehaus Capital +3	6	—	92d Ph2	95
OLMA Olema Pharmaceuticals, Inc.	Exited Avoro Capital Advisors, Perceptive Advisors +3	2	—	30d Ph3	95
RCUS Arcus Biosciences Inc.	Exited Eventide Asset Management, RA Capital Management +3	1	—	30d Ph3	95
DSGN Design Therapeutics, Inc.	Exited EcoR1 Capital, Baker Bros. Advisors +3	3	—	110d Ph3	95
FDMT 4D Molecular Therapeutics, Inc.	Trimmed RA Capital Management, BVF Partners +2	3	—	30d Ph2	95
MLTX MoonLake Immunotherapeutics	Exited OrbiMed Advisors, EcoR1 Capital +4	2	—	120d Ph3	95
EXAS Exact Sciences Corporation	Exited Driehaus Capital, Rock Springs Capital +3	3	—	198d Ph2	95
EWTX Edgewise Therapeutics, Inc.	Exited EcoR1 Capital, Driehaus Capital +2	4	—	30d Ph2	95
INSM Insmed Incorporated	Exited OrbiMed Advisors, Driehaus Capital +3	4	—	214d Ph3	95
NUVL Nuvalent Inc.	Exited Baker Bros. Advisors, Driehaus Capital +3	3	—	—	90
CNTA Centessa Pharmaceuticals plc	Added Perceptive Advisors, Cormorant Asset Management +3	2	—	214d Ph2	90
ITOS iTeos Therapeutics SA	Exited EcoR1 Capital, OrbiMed Advisors +3	3	—	—	90
ABOS Acumen Pharmaceuticals, Inc.	Added RA Capital Management, Rock Springs Capital +3	1	—	153d Ph2	90
ETNB 89bio Inc.	Exited RA Capital Management, Driehaus Capital +3	5	—	—	90
CTMX CytomX Therapeutics Inc.	Exited OrbiMed Advisors, Commodore Capital +3	3	—	—	90
QURE uniQure N.V.	Exited Perceptive Advisors, RTW Investments +4	—	—	—	90
CLDX Celldex Therapeutics Inc.	Trimmed Eventide Asset Management, EcoR1 Capital +4	1	—	—	90
TNGX Tango Therapeutics Inc.	Exited RA Capital Management, Cormorant Asset Management +3	4	—	—	90
AAVXF Abivax S.A.	Added OrbiMed Advisors, Commodore Capital +3	2	—	214d Ph2	90
RLAY Relay Therapeutics Inc.	Added EcoR1 Capital, BVF Partners +2	3	—	—	85
ORKA Oruka Therapeutics, Inc.	New Rock Springs Capital, Perceptive Advisors +2	—	—	395d Ph2	85
ARGX argenx SE	Exited Perceptive Advisors, EcoR1 Capital +3	2	—	61d Ph2	80
VRNA Verona Pharma plc	Exited Baker Bros. Advisors, EcoR1 Capital +3	2	—	66d Ph2	80
TYRA Tyra Biosciences, Inc.	Exited Perceptive Advisors, EcoR1 Capital +2	3	—	183d Ph2	80
PTCT PTC Therapeutics Inc.	Trimmed Driehaus Capital, Baker Bros. Advisors +2	—	—	30d Ph3	80
APGE Apogee Therapeutics Inc.	Exited RA Capital Management, Tang Capital Management +3	2	—	183d Ph2	80
MGNX MACROGENICS INC	Exited Baker Bros. Advisors, EcoR1 Capital +3	2	—	273d Ph2	80
BMRN BioMarin Pharmaceutical Inc.	Exited Perceptive Advisors, Baker Bros. Advisors +2	1	—	30d Ph2	80
ALXO ALX ONCOLOGY HOLDINGS INC	New RA Capital Management, Driehaus Capital +2	1	—	—	80
AXSM Axsome Therapeutics Inc.	Trimmed Deep Track Capital, RA Capital Management +2	4	—	184d Ph2	80
DAWN Day One Biopharmaceuticals Inc.	Exited EcoR1 Capital, Commodore Capital +3	2	—	365d Ph2	80
AKTS Aktis Oncology, Inc.	New RA Capital Management, Driehaus Capital +2	—	—	—	80

Showing 50 of 428

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why PCVX is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days. Card required, no charge until day 15. Cancel anytime.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →